Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 24.6%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 82,236 shares, an increase of 24.6% from the March 15th total of 65,987 shares. Based on an average daily volume of 46,188 shares, the short-interest ratio is presently 1.8 days. Approximately 2.2% of the company’s stock are short sold.

Institutional Trading of vTv Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics in the fourth quarter valued at about $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter valued at about $731,000. Geode Capital Management LLC increased its stake in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP increased its stake in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares during the period. Institutional investors own 17.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on VTVT shares. BTIG Research reissued a “buy” rating and set a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Evercore started coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. Roth Mkm started coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price for the company. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, TD Cowen started coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Stock Performance

Shares of VTVT traded up $0.49 during trading hours on Friday, reaching $37.24. 15,163 shares of the company traded hands, compared to its average volume of 42,200. The stock’s fifty day moving average is $36.64 and its 200 day moving average is $32.47. The stock has a market cap of $146.67 million, a P/E ratio of -11.11 and a beta of 0.40. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.